[New therapeutic approaches in glioblastomas].
New therapeutic approaches based on the understanding of brain tumour biology are emerging. Signal transduction inhibitors (mainly targeted against the EGF receptor, the PI3K/Akt or the Ras/Raf pathways), proteases inhibitors and antiangiogenic agents are currently under investigations in clinical trials. The recent development of convection-enhanced delivery technique allows the administration of drugs which do not cross the blood-brain-barrier, such as selective toxins or immunostimulating oligonucleotides. This article reviews these emerging therapies currently under clinical trials in glioblastomas.
Carpentier
Antoine F
AF
Service de neurologie, Hôpital de la Salpêtrière, 57, bd de l'hopital, 75013 Paris. antoine.carpentier@psl.ap-hop-paris.fr
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001812:Blood-Brain Barrier; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics; D002869:Chromosome Aberrations; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005909:Glioblastoma / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors; D051057:Proto-Oncogene Proteins c-akt; D019908:Proto-Oncogene Proteins c-raf / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; C494918:AKT1 protein, human; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt; D019908:Proto-Oncogene Proteins c-raf